European Psychiatry - Volume 41 - April 2017

848 / 916

S844 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S772–S846
Parkinson’s disease shouldbe careful for the likely increase inmotor
clinical and increased mortality. The most useful, are especially
quetiapine and clozapine atypical antipsychotics.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1338
Muscarinic mechanisms in psychosis:
A multimodal imaging study
T. Van Amelsvoort
Maastricht University, Department of Psychiatry and Psychology,
Maastricht, The Netherlands
Background The majority of people with psychosis suffer from
cognitive problems. These cognitive problems are among the most
disabling features of the illness and have a negative effect on clinical
outcome. Research has demonstrated that acetylcholine including
muscarinic receptors play an important role in cognitive function. A
post-mortem study in chronic patients with schizophrenia demon-
strated a decrease of 75% of muscarinic M1 receptors.
Aim The aimof this studywas to investigate the role of M1 recep-
tors in-vivo in brain and cognitive function in psychosis.
Methods Thirty medication free patients with psychosis and 30
healthy controls matched for age, gender and IQ were included for
1) 1x IDEX Spect scan to determine M1 binding potential; 2) 2x
fMRI scan using a visual memory task; 3) 2x MRS to determine
choline concentrations; 2x CANTAB cognitive battery. Except for
SPECT all subjects were tested twice, once with placebo and once
with biperiden M1 antagonist.
Resultaten Patients demonstrated a significant negative corre-
lation between M1 binding potential and cognitive impairments
and negative symptom scores on PANSS. Following biperiden chal-
lenge, performance on verbal learning and memory was worse.
Hippocampal activity was larger during a visual memory task in
patients.
Conclusie These results support a role for the M1 receptor in cog-
nitive function in psychosis.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EV1339
Schizophrenia and obsessive
compulsive disorder
K. Vrbova ∗, J. Prasko , A. Cinculova , B. Krnacova , B. Talova ,
A. Tichackova , K. Latalova
Faculty of Medicine and Dentistry, Palacky University and University
Hospital Olomouc, Department of Psychiatry, Olomouc, Czech
Republic
∗ Corresponding author.
Introduction A recent reviews of published researchers suggest,
that up to 25% of schizophrenia patients suffer from obsessive-
compulsive symptoms (OCs) and about 12% fulfill the diagnostic
criteria for obsessive-compulsive disorder (OCD). Recently, the
interest in this issue has significantly increased, probably due to
the finding, that second generation antipsychotics, especially cloza-
pine, might induce or aggravate OCs.
Objective The aim of our study was to investigate and clarify the
literature data about the extent to which comorbid OCs affects the
severity and course of schizophrenia.
Methods The articles were identified by the keywords
“schizophrenia comorbidity” and “obsessive compulsive dis-
order”, using the medline and web of science search. Additional
information was obtained by studying the references of summaries
of relevant articles.
Results Obsessive-compulsive symptoms or fully expressed
obsessive-compulsive disorder leads to more severe overall psy-
chopathology and poorer treatment outcomes in patients with
schizophrenia. This comorbidity is accompanied by increased neu-
rocognitive impairment, high levels of anxiety, depression, and
suicidality, less favorable levels of social and vocational functioning,
and greater social and health service utilization.
Conclusions In clinical practice, schizophrenia patients should
be carefully monitored for OCs, which may occur at any time
during the schizophrenia disease. Early recognition and targeted
treatment of this comorbidity reduce patient’s distress; positively
influence the course of illness and overall treatment outcome.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1340
Comorbidity of schizophrenia and
social phobia
K. Vrbova ∗, J. Prasko , K. Latalova , D. Kamaradova ,
M. Ociskova , Z. Sedlackova
1 Faculty of Medicine and Dentistry- Palacky University and
University Hospital Olomouc, Department of Psychiatry, Olomouc,
Czech Republic
2 Faculty of Arts- Palacky University Olomouc, Department of
Psychology, Olomouc, Czech Republic
∗ Corresponding author.
Introduction The most common comorbid disorder in
schizophrenic patients is a social phobia. It is usually an unrecog-
nized problem that may be associated with a high distortion in
managing claims of life.
Objectives The aim of our study was to determine the extent to
which comorbid social phobia affects the severity and course of
schizophrenia.
Methods The publications were identified in the database med-
line and web of science using the keywords “schizophrenia
comorbidity” in combination with the terms “social phobia” or
“social anxiety disorder”. Other relevant sources of information
were obtained from the cited works by important articles.
Results The current state of research shows that the incidence
of comorbid social phobia in psychotic disease states in the range
from11% to 36%. Social phobia in psychotic patients remains largely
unrecognized. An untreated social phobia is associated with more
severe psychotic symptoms, worse quality of life and lower self-
esteem. It also increases the tendency to social isolation and overall
worsens social adaptation. Patients with comorbid social pho-
bia and schizophrenia have a higher amount of lifetime suicide
attempts and often abuse alcohol or addictive substance.
Conclusions Patients who have both schizophrenia and social
phobia have a lower quality of life, impaired functioning in life,
a higher incidence of suicide attempts and increased risk of relapse
of psychosis. It is, therefore, necessary that physicians treating the
patients with schizophrenia had inmind the possibility of the pres-
ence of comorbid social phobia, and in the case of its occurrence,
they also treat it.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1341
Schizoaffective disorder and life
quality
W. Bouali ∗, I. Marrag , F. Ellouze , A. Dekhil , M. Nasr
Hospital, psychiatrie, Mahdia, Tunisia
∗ Corresponding author.